Clinical trial Recruiting at 1 site Observational Ages 18 and up

Low-flow ECCO2R for ICU patients with respiratory failure: safety and outcomes

Official title: Retrospective Cohort Study of Low-Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) System: Evaluating Efficacy and Safety

Run by Hong Kong University · NCT07161271 · Data updated 2026-11-12

This review looks back at adults in the ICU who received low-flow ECCO2R to see if the treatment was safe and helped people with respiratory failure, including ARDS and severe asthma.

More Respiratory Failure trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment59 (estimated)
SponsorHong Kong University
Academic / other
Locations1 site (Hong Kong)
StatusRecruiting
StartedNovember 1, 2024
Main results expectedDecember 31, 2026
Study endsJune 30, 2027
Registry record updatedDecember 23, 2025
Trial IDNCT07161271 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18 years or older) who were admitted to the ICU at Queen Mary Hospital and received low-flow ECCO2R between January 1, 2022 and June 30, 2024 are the subjects of this review.

Probably not a fit

Patients who were not treated with ECCO2R, treated at other hospitals, or under 18 years old would not be represented and so would not directly benefit from the study's conclusions.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective chart review of adult patients treated with low-flow extracorporeal carbon dioxide removal (ECCO2R) at Queen Mary Hospital between January 1, 2022 and June 30, 2024. The team will describe which patients were selected for ECCO2R, specific technical and clinical management choices, and short-term clinical outcomes and adverse events. Data will be drawn from routinely collected ICU records to characterize practice patterns and complications associated with low-flow systems. The goal is to identify factors that could improve the quality and safety of ECCO2R use in critically ill patients.

Why it matters

Potential benefit: If findings show favorable safety and outcomes, clinicians could better select patients and manage low-flow ECCO2R to reduce complications and improve ICU care.

How similar studies have gone: Previous small trials of ECCO2R have produced physiological benefits such as reduced ventilator intensity but have not consistently shown improved mortality, and low-flow systems remain less well studied.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients supported with ECCO2R in one of the designated study sites
* Admitted to the ICU between 1 Jan 2022 and 30 June 2024

Exclusion Criteria:

* Patients younger than 18 years old

Where it's running

  • Queen Mary Hospital (QMH)
    Hong Kong, Hong Kong
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.